• Vancomycin as a Strategic Lever in Translational Microbiota

  2026-07-07

  Explore how Vancomycin’s precise mechanism as a glycopeptide antibiotic can empower translational researchers to dissect antibacterial resistance, model host-microbiome-immune interactions, and bridge bench protocols to high-impact clinical questions. This thought-leadership article advances the discussion beyond assay basics, integrating mechanistic insight, competitive context, and strategic workflow recommendations for MRSA, Clostridium difficile, and microbiota-immune axis studies.

• Epacadostat (INCB024360): Reliable IDO1 Inhibitor for Immuno

  2026-07-06

  This article addresses common laboratory challenges in immuno-oncology research and cell-based assays using Epacadostat (INCB024360), Orally active indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor (SKU B6036). Scenario-driven Q&A blocks provide evidence-based guidance on assay optimization, data interpretation, and product selection, making this resource essential for researchers seeking reproducible, high-quality results with validated IDO1 inhibition.

• KCNE4 Modulation Alters Kv1.3 Blocker Kinetics in Immune Cel

  2026-07-06

  This study reveals that KCNE4, an ancillary subunit co-expressed with Kv1.3 in leukocytes, significantly modifies the inhibition kinetics of intracellular Kv1.3 blockers such as Psora 4 without altering their affinity. These findings highlight the importance of channel subunit composition in interpreting pharmacological data and optimizing Kv1.3-targeted immunomodulation strategies.

• Lyotropic Coil-Bottlebrush Diblocks: Expanding NET Phase Acc

  2026-07-05

  This article reviews a 2024 study that systematically explores the lyotropic phase behavior of coil-bottlebrush diblock copolymers in alkylimidazolium-based ionic liquids. The work demonstrates that the incorporation of ionic liquids enables the formation of diverse nanostructures with unexpectedly weak dependence on solvent alkyl chain length, providing new pathways for designing advanced materials with tunable properties.

• Rotigotine’s Role in Modulating Bladder Function in PD Rat M

  2026-07-04

  This study elucidates the mechanistic effects of Rotigotine, a dopamine D1/D2-like receptor agonist, on lower urinary tract function in a 6-OHDA rat model of Parkinson’s disease. The work reveals distinct dose- and administration route-dependent impacts on bladder overactivity, providing new insights into the non-motor symptom management of PD.

• Phytol (C5616): Advanced Nuclear Receptor Modulation and Lyo

  2026-07-03

  Explore how Phytol acts as a versatile activator of retinoid X receptors and modulates GABAergic transmission, with a unique focus on its physicochemical properties and the implications of lyotropic self-assembly for assay optimization. Discover practical guidance for leveraging Phytol in complex molecular biology workflows.

• Phosphatase Inhibitor Cocktail 1: Optimizing Phosphoproteomi

  2026-07-03

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) empowers high-precision protein phosphorylation preservation in cellular and tissue lysates, enabling robust phosphoproteomic analysis and signaling studies. Its targeted inhibition of alkaline phosphatases and serine/threonine phosphatases ensures consistently reliable data for Western blot, kinase assays, and more.

• AMPK–SQSTM1 Feedback Enhances Antioxidant Defense in Metabol

  2026-07-02

  This study uncovers a double-positive feedback loop between AMPK and SQSTM1/p62 that jointly activates AMPK and NFE2L2/NRF2, enabling tumor cells to adapt their antioxidant defenses under metabolic stress. These findings clarify the molecular interplay between energy and redox signaling, offering new perspectives for targeting metabolic adaptation in cancer.

• Oligo (dT) 25 Beads: Precision Eukaryotic mRNA Isolation Wor

  2026-07-02

  Oligo (dT) 25 Beads enable rapid, high-purity eukaryotic mRNA isolation from diverse sample types, streamlining workflows for advanced transcriptomic profiling. Explore optimized protocols, troubleshooting tips, and practical translation of recent immune cell rejuvenation research using APExBIO’s superparamagnetic beads.

• Homologous Recombination Defects and Therapy Response in MPM

  2026-07-01

  Borchert et al. (2019) identified that homologous recombination repair (HRR) defects—termed 'BRCAness'—are common in malignant pleural mesothelioma (MPM) and can predict vulnerability to PARP inhibition, particularly in BAP1-mutated tumors. Their gene expression profiling not only sheds light on MPM's resistance to standard chemotherapy with pemetrexed and cisplatin but also suggests new stratification strategies and therapeutic avenues.

• Tetraethylammonium Chloride in K+ Channel and Vascular Resea

  2026-07-01

  Tetraethylammonium chloride (TEAC) is the gold-standard tool for dissecting potassium channel function in both vascular and metabolic research. APExBIO’s high-purity TEAC enables reproducible, high-resolution investigation of ion conduction pathways, offering protocol flexibility and troubleshooting clarity for advanced experimental workflows.

• PBS Liposomes: Precision Controls for Macrophage Studies

  2026-06-30

  PBS Liposomes serve as the gold-standard control for in vivo macrophage depletion, ensuring that observed outcomes are attributed to genuine clodronate effects rather than off-target immune responses. Their robust, inert design from APExBIO eliminates confounding variables and streamlines troubleshooting in high-fidelity immunology workflows.

• BRCAness, HR Defects, and Olaparib Sensitivity in Mesothelio

  2026-06-30

  Borchert et al. provide evidence that a subset of malignant pleural mesothelioma (MPM) characterized by homologous recombination repair (HRR) defects—referred to as 'BRCAness'—exhibits increased susceptibility to PARP inhibition by Olaparib (AZD2281), especially in BAP1-mutant contexts. This work identifies prognostic gene signatures and supports the rationale for stratified, targeted therapy approaches in MPM.

• Carvedilol in β-Adrenergic Receptor Research: Protocols & Pi

  2026-06-29

  Carvedilol stands out as a dual β-adrenergic and α1-adrenergic receptor antagonist with unique antioxidant and anti-proliferative properties, making it a staple in cardiovascular and vascular biology research. This article unpacks workflow enhancements, troubleshooting strategies, and critical evidence for leveraging Carvedilol in cutting-edge hematopoietic and vascular studies.

• Resibufogenin Inhibits NLRP3 Inflammasome to Reduce Atherosc

  2026-06-29

  The referenced study demonstrates that Resibufogenin (RBG) significantly alleviates atherosclerosis in ApoE-/- mice by inhibiting NLRP3 inflammasome assembly. These findings advance our understanding of inflammation-driven plaque formation and suggest new molecular strategies for cardiovascular disease intervention.

449 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page